Asia
CENTOGENE biomarker measures lyso-Gb1 levels in children
Taiwan Liposome Company, Ltd. announced the signing of a development and license agreement with Birdie Biopharmaceuticals Inc., a wholly owned subsidiary of Seven and Eight Biopharmaceuticals Corp.
Glenmark said it should be able to resolve the FDA’s concerns within six to nine weeks and will work with the regulatory agency toward approval.
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
Scientists from the Agency for Science, Technology and Research’s Genome Institute of Singapore have identified two new Epstein-Barr Virus viral variants associated with cancers, including nasopharyngeal carcinoma, gastric cancer, and several kinds of lymphomas[2].
Trade tensions between Washington, D.C. and Beijing continue, but have not yet impacted the pharmaceutical products traded between the two countries. However, if the punitive tariffs continue and pharma is impacted, a third global player could step in to fill the void in both countries.
The companies will combine their research expertise to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.
Todos Medical Ltd. announced that CEO Herman Weiss, MD, MBA, FACOG, provided a corporate update and roadmap at LD Micro International Annual Invitational in Los Angelos, California.
Chinese companies that gain toeholds in the U.S. are poaching executives from U.S. companies who have significant clinical and regulatory experience.
TLC, announced results from the pre-planned analysis of Part 1 of TLC590’s Phase II clinical trial in patients following bunionectomy.
PRESS RELEASES